-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Allogene Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q4 2017 to Q4 2024.
- Allogene Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$59.9M, a 30.1% increase year-over-year.
- Allogene Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$258M, a 21.3% increase year-over-year.
- Allogene Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$258M, a 21.3% increase from 2023.
- Allogene Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$327M, a 3.86% increase from 2022.
- Allogene Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$340M, a 87% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)